Edgewise Therapeutics
Clinical trials sponsored by Edgewise Therapeutics, explained in plain language.
A clinical-stage biopharmaceutical company developing muscle disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to slow muscle damage in becker MD Results expected Sep 2026 (estimated)
- New drug trial hopes to slow muscle damage in kids with DMD Results expected Jan 2027 (estimated)
- New hope for duchenne kids: drug combo after gene therapy tested Results expected Mar 2027 (estimated)
-
New drug EDG-15400 tested in healthy people for first time
Knowledge-focused CompletedThis early-stage study is testing a new oral drug called EDG-15400 in 108 healthy adults aged 18 to 59. The main goal is to check if the drug is safe and how well it is tolerated, both after a single dose and after multiple doses. Researchers will also measure how much of the dru…
Phase 1 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New drug EDG-7500 tested in healthy volunteers
Knowledge-focused CompletedThis early-stage study tests the safety of a new drug called EDG-7500 in 24 healthy adults, both Japanese and Caucasian. Participants receive single or multiple doses, and researchers measure how the drug moves through the body. No treatment benefit is expected; the goal is to ga…
Phase 1 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New drug EDG-7500 put to the test in liver health study
Knowledge-focused CompletedThis early-stage study is testing a single dose of an experimental drug called EDG-7500 in 32 adults. Some have mild or moderate liver problems, while others have normal liver function. Researchers want to see how the drug moves through the body and if it is safe in people with d…
Phase 1 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Kidney function may affect drug levels: new study completed
Knowledge-focused CompletedThis study looked at how a single dose of the drug EDG-7500 stays in the blood of people with various levels of kidney function, from normal to severely impaired. It involved 37 adults aged 18-75. The goal was to understand if kidney problems change drug levels, which helps docto…
Phase 1 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC